Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70950 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ruth P Lim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Austin Health, Heidelberg, Australia. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Kidney. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim, Royal Australian and New Zealand College of Radiologists.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue oxygenation and microstructure. Materials and Methods Prospective randomised open‐label crossover clinical trial of adults with T2DM with eGFR ≥ 45 mL/min/1.73 m 2 and any degree of albuminuria (CKD KDIGO G1, 2 or GF3a, A1–A3). MpMRI was performed at baseline and 12‐weeks post‐empagliflozin or active comparator sitagliptin therapy in random order with an interval washout period. Brochner‐Mortensen corrected MRI‐derived GFR (MRI‐GFR), renal vascular resistance (RVR), renal blood flow (RBF) and markers of tissue hypoxia (R2*) and microstructure were measured. Impact of empagliflozin or sitagliptin on MpMRI and laboratory metrics were assessed with mixed‐effect linear regression.
Results
Twelve participants (8 male, 4 female) completed all study visits. Following empagliflozin, there were significant mean decreases in MRI‐GFR (3.03 mL/min/1.73 m 2 ) and RBF (41.24 mL/min) and increased medullary hypoxia (R2* 1.81 s −1 ) compared to sitagliptin, all p < 0.05. There were no statistically significant changes to RVR, corticomedullary microstructure, eGFR or albuminuria observed with empagliflozin.
Conclusions
Multiparametric MRI can non‐invasively demonstrate local renal impacts of empagliflozin beyond that of traditional markers of renal function, including decreased GFR and medullary hypoxia. Lack of RVR change may relate to lower systemic blood pressure, concurrent medication and efferent arteriolar vasodilation in T2DM. Trial Registration: ACTRN12619000933156
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Austin Health, Heidelberg, Australia.
- Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia.
- Australian Centre for Accelerating Diabetes Innovations, School of Medicine, University of Melbourne, Parkville, Australia.
- Department of Medicine, St Vincent's Hospital Melbourne, University of Melbourne, Fitzroy, Australia.
- Department of Endocrinology and Diabetes, St Vincent's Hospital Melbourne, Fitzroy, Australia.
ORCID-Profile: Ruth P Lim, Elif I Ekinci
Förderung
- Boehringer Ingelheim
- Royal Australian and New Zealand College of Radiologists
Zitieren
APA
Lim, R. P., Qassin, S., McKenna, L., Hornsey, E., Italiano, D., Churilov, L., MacIsaac, R. J., Seah, J. M., Ekinci, E. I., & Austin EMPA‐MRI Study Group (2026). Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70950
Vancouver
Lim RP, Qassin S, McKenna L, Hornsey E, Italiano D, Churilov L, et al. Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70950
BibTeX
@article{Lim2026,
author = {Lim, Ruth P and Qassin, Salma and McKenna, Lucy and Hornsey, Emma and Italiano, Dominic and Churilov, Leonid and MacIsaac, Richard J and Seah, Jas-Mine and Ekinci, Elif I and Austin EMPA‐MRI Study Group, Austin EMPA‐MRI Study Group},
title = {Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70950}
}
EUVIMED